- Home
- MS vs ABBV Comparison
MS vs ABBV Comparison
Compare MS & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MS | ABBV |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | United States |
| Employees | 83000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.0B | 358.5B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MS | ABBV |
|---|---|---|
| Price | $211.69 | $247.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 18 |
| Target Price | ★ $337.93 | $253.71 |
| AVG Volume (30 Days) | ★ 4.9M | 4.1M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | 2.14% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $12.22 | $11.87 |
| Revenue Next Year | $5.62 | $8.12 |
| P/E Ratio | ★ $17.30 | $625.28 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $135.31 | $181.75 |
| 52 Week High | $230.47 | $244.81 |
Technical Indicators
Market Signals| Indicator | MS | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 75.20 |
| Support Level | $205.83 | $213.65 |
| Resistance Level | $219.16 | N/A |
| Average True Range (ATR) | 5.79 | 5.90 |
| MACD | -0.94 | 2.32 |
| Stochastic Oscillator | 26.18 | 99.62 |
Price Performance
Historical ComparisonAbout MS Morgan Stanley
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of 2025. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.